Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

15.79 +0.68 (+4.50%)
Streaming Delayed Price Updated: 3:31 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
This Unstoppable Biotech Stock Just Became an Even Better Buy ↗
Via The Motley Fool
News headline image
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Is Summit Therapeutics a Millionaire Maker? ↗
Via The Motley Fool
News headline image
2 Stocks That Could Soar Again in 2025 ↗
Via The Motley Fool
News headline image
Why Summit Therapeutics Rocketed 584% in 2024 ↗
Via The Motley Fool
News headline image
Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗
Top 10 large-cap stocks rose last week: Rubrik 23.17%, Applovin 17.21%, Summit Therapeutics 16.93%, Intel 16.52%, VG 16.03%, GE Vernova 14.01%, Samsara 11.96%, Antero Resources 11.68%, Super Micro... 
Via Benzinga
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Why Summit Therapeutics Stock Was Winning This Week ↗
Via The Motley Fool
News headline image
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year ↗
Via The Motley Fool
News headline image
2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger ↗
Via The Motley Fool
News headline image
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown ↗
Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors. 
Via Stocktwits
News headline image
Palantir Extends Losses, Microsoft Slides: What's Driving Markets Monday? ↗
The major indices struggled to maintain early momentum on Monday, but appear to climbing back with the S&P 500 and Dow Jones both green in midday trading.  
Via Benzinga
Topics Stocks
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 24, 2025 ↗
 
Via Benzinga
News headline image
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday? ↗
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.  
Via Benzinga
News headline image
Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025
From Summit Therapeutics Inc.
Via Business Wire
News headline image
3 Stocks That Could Trounce the Market in 2025 ↗
Via The Motley Fool
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There' ↗
On CNBC's "Mad Money Lightning Round," Jim Cramer said Summit Therapeutics is "obviously just a very big spec." 
Via Benzinga
News headline image
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? ↗
Via The Motley Fool
News headline image
Netflix, Palantir And Moderna Are Among Top 12 Large Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio? ↗
12 large-cap stocks saw significant gains last week, including Summit Therapeutics, Rocket Lab, Moderna, and Netflix. Analysts raised price forecasts. 
Via Benzinga
News headline image
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35% ↗
Via The Motley Fool
News headline image
Why Summit Therapeutics Stock Is Jumping Today ↗
Via The Motley Fool
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst ↗
Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025. 
Via Benzinga
News headline image
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.